Literature DB >> 21674859

Frequency and prognostic impact of FLT3/ITD mutation in patients with acute myeloid leukaemia.

N Govedarovic1, G Marjanovic.   

Abstract

PURPOSE: This study was designed to evaluate the prevalence and the prognostic significance of fms-like tyrosine kinase-3 internal tandem duplication (FLT3/ITD), in acute myeloid leukaemia (AML).
METHODS: We reviewed 123 newly diagnosed AML patients who have been treated at the Clinic of Hematology, Clinical Center of Nis, Serbia, during a 5-year period. The correlation between presence of the FLT3/ITD mutation and the subtype of disease according to FAB classification, white blood cell count, incidence of early relapse (<12 months) and overall survival was studied.
RESULTS: Among 103 patients for whom molecular analyses had been done, FLT3/ITD mutation was present in 46 (44.7%) cases; the highest frequency was seen in the M0 subtype (63.6%), and the lowest in the M1 subtype (16.7%). There were no statistically significant differences in the FLT3/ITD presence for the 3 groups of patients having different leucocyte counts. The FLT3/ITD mutation was associated with a higher incidence of early relapse compared with no mutation cases (78.7 vs. 21.4%; p < 0.001), and with a shorter survival time (<40 vs. >60 months; p < 0.001).
CONCLUSION: The FLT3/ITD mutation is a poor prognostic factor, which occurs frequently in AML, and is associated with higher incidence of early disease relapse and shorter overall survival.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21674859

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  4 in total

1.  FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation.

Authors:  Shanhao Tang; Hongjie Shen; Xinliang Mao; Haiping Dai; Xiaming Zhu; Shengli Xue; Zixuan Ding; Jing Lu; Depei Wu; Xiaowen Tang
Journal:  Int J Hematol       Date:  2017-06-14       Impact factor: 2.490

2.  Maintenance sorafenib is superior to prophylactic donor lymphocyte infusion at improving the prognosis of acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplication after allogeneic hematopoietic stem cell transplantation.

Authors:  Jimin Shi; Liqin Cao; Yi Luo; Yanmin Zhao; Yamin Tan; Jian Yu; Xiaoyu Lai; Yuanyuan Zhu; Yongxian Hu; Jingsong He; Jie Sun; Weiyan Zheng; Guoqing Wei; He Huang
Journal:  Bone Marrow Transplant       Date:  2020-08-04       Impact factor: 5.483

3.  Acute myeloid leukemia patient with FLT3-ITD and NPM1 double mutation should undergo allogeneic hematopoietic stem cell transplantation in CR1 for better prognosis.

Authors:  Yan Huang; Juan Hu; Ting Lu; Yi Luo; Jimin Shi; Wenjun Wu; Xiaoyan Han; Weiyan Zheng; Jingsong He; Zhen Cai; Guoqing Wei; He Huang; Jie Sun
Journal:  Cancer Manag Res       Date:  2019-05-08       Impact factor: 3.989

4.  Suberoylanilide hydroxamic acid induces hypersensitivity to radiation therapy in acute myelogenous leukemia cells expressing constitutively active FLT3 mutants.

Authors:  Xufeng Chen; Eric H Radany; Patty Wong; Shenglin Ma; Kan Wu; Bing Wang; Jeffrey Y C Wong
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.